N Svartz
- Anatomy top 2%
- Rheumatology top 10%
- Rheumatoid Arthritis Research and Therapies 15
- Systemic Lupus Erythematosus Research 6
- Genetics top 10%
- Diabetes and associated disorders 5
- Chronic Lymphocytic Leukemia Research 3
- Blood disorders and treatments 3
- Gastroenterology top 10%
- Pharmacology top 10%
-
- Monoclonal and Polyclonal Antibodies Research 16
-
- Microscopic Colitis 4
-
- HER2/EGFR in Cancer Research 4
- Cited by
- AnatomyRheumatologyGenetics
- Partner nations
- SwedenUnited States
In The Last Decade
N Svartz
49 papers receiving 438 citations
Peers
Comparison fields: 5 of 74
- Anatomy 17
- Rheumatology 157
- Genetics 187
- Gastroenterology 32
- Pharmacology 48
Countries citing papers authored by N Svartz
This map shows the geographic impact of N Svartz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by N Svartz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites N Svartz more than expected).
Fields of papers citing papers by N Svartz
This network shows the impact of papers produced by N Svartz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by N Svartz. The network helps show where N Svartz may publish in the future.
Co-authorship network
The 7 scholars most cited alongside N Svartz, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 1969 | 2 | |
| 2 | Treatment of ulcerative colitis with salazopyrin. | 1968 | 7 |
| 3 | Macroglobulins in chronic pancreatitis and liver cirrhosis. Comparison with the rheumatoid factor macroglobulin. | 1967 | 1 |
| 4 | 1964 | 1 | |
| 5 | [STUDIES ON RHEUMATOID FACTOR]. | 1963 | 0 |
| 6 | 1961 | 1 | |
| 7 | 1959 | 3 | |
| 8 | Serological tests for the differential diagnosis of rheumatic diseases. | 1959 | 3 |
| 9 | [On the origin of colon carcinoma in ulcerative colitis]. | 1959 | 1 |
| 10 | 1959 | 2 | |
| 11 | 1958 | 9 | |
| 12 | 1957 | 7 | |
| 13 | 1956 | 5 | |
| 14 | 1956 | 1 | |
| 15 | 1954 | 35 | |
| 16 | 1953 | 26 | |
| 17 | 1952 | 2 | |
| 18 | 1952 | 52 | |
| 19 | 1951 | 9 | |
| 20 | 1951 | 6 |
About N Svartz
N Svartz is a scholar working on Rheumatology, Radiology, Nuclear Medicine and Imaging and Pharmacology, having authored 65 papers that have together received 644 indexed citations. Recurring topics across this work include Monoclonal and Polyclonal Antibodies Research (16 papers), Rheumatoid Arthritis Research and Therapies (15 papers), Systemic Lupus Erythematosus Research (6 papers), Diabetes and associated disorders (5 papers), Microscopic Colitis (4 papers), HER2/EGFR in Cancer Research (4 papers), Chronic Lymphocytic Leukemia Research (3 papers) and Blood disorders and treatments (3 papers). The work is most often cited by research in Anatomy (17 citations), Rheumatology (157 citations) and Genetics (187 citations). N Svartz has collaborated with scholars based in Sweden and United States. Frequent co-authors include K Schlossmann, Sven Ullberg, Å Hanngren, Emma Hansson, A Ehrenberg, Lars A. Carlson and B.F. Ericsson. Their work appears in journals such as Annals of the Rheumatic Diseases, Digestion, JAMA, Scandinavian Journal of Rheumatology and Inflammation Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.